New research and development contract award for the feasibility study of a single platform solution for blood testing of traumatic brain injury biomarkers for the congressionally directed medical…
Ended Definitive Contract Awarded Last action
- Contract number
- W81XWH22C0059
- Awardee
-
Gryphon Bio Inc. UEI GNX8BTRL8915
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $749,437
Award facts
- Opportunity
-
- W81XWH21STBIP Solicitation number
- Contract value 100% obligated
- $749,437.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 102 offers Basic Research
- Pricing
- Fixed Price Level of Effort
- Place of performance
- South San Francisco, CA 94080, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Change Order | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $749,437 |
About this award
The Defense Health Agency awarded a $749,437 definitive fixed-price level-of-effort contract to Gryphon Bio Inc. for a feasibility study of a single platform solution for blood testing of traumatic brain injury biomarkers on September 26, 2022, under the Congressionally Directed Medical Research Program Office.
Place of performance is South San Francisco, CA. The contract runs through June 24, 2026. The effort addresses development of a unified diagnostic platform capable of detecting TBI biomarkers through blood testing, supporting the Defense Health Agency's research priorities in traumatic brain injury diagnostics and treatment advancement.
Description
New research and development contract award for the feasibility study of a single platform solution for blood testing of traumatic brain injury biomarkers for the congressionally directed medical research program office
Quick answers
Who was awarded contract W81XWH22C0059?
W81XWH22C0059 was awarded to Gryphon Bio Inc. by Defense Health Agency (Department of Defense) on September 26, 2022.
How much is contract W81XWH22C0059 worth?
The government has obligated $749,437 on W81XWH22C0059.
Was contract W81XWH22C0059 competed?
The extent of competition for W81XWH22C0059 was full and open competition. The government received 102 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award